SCHEMBL1372811

SCHEMBL1372811

N#Cc1ccccc1OB(O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.46
POLB P06746 1/20 0.46
TSHR P16473 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.41
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 4/20 0.40
HPGD P15428 1/20 0.40
AR P10275 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
ADRA2B P18089 1/20 0.39
MAOA P21397 1/20 0.39
HTR2B P41595 1/20 0.39
ESR2 Q92731 1/20 0.37
TP53 P04637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PDE4A P27815 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30517279 1.00 GAA (0.46) GAAPOLBTSHRSMN1; SMN2MAPK1
1,3-Propanediol SCHEMBL28556057 0.89 SMN1; SMN2 (0.39) GAAPOLBTSHRSMN1; SMN2MAPK1
SCHEMBL31189733 0.82 TSHR (0.36) GAAPOLBTSHRSMN1; SMN2MAPK1
SCHEMBL31355745 0.82 SMN1; SMN2 (0.38) GAAPOLBTSHRSMN1; SMN2MAPK1
SCHEMBL30957147 0.81 TSHR (0.44) GAAPOLBTSHRSMN1; SMN2MAPK1
SCHEMBL31019102 0.79 FABP7 (0.35)
SCHEMBL30441431 0.77 IMPDH2 (0.61) TSHRAR
SCHEMBL30522390 0.77 AR (0.42) ALDH1A1HPGDARMAOAKDM4E
SCHEMBL6678412 0.77 ENPP2 (0.44) GAATSHRSMN1; SMN2ALDH1A1HPGD
SCHEMBL29706601 0.77 ENPP2 (0.44) GAATSHRSMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118772131-A Biaryl compound and preparation method and application thereof 河南大学 2024-10-15 CN claimed
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP claimed
JP-11152269-A None JP disclosed
CN-117497840-A Gel electrolyte, preparation method thereof and sodium ion battery 广东省豪鹏新能源科技有限公司 2024-02-02 CN disclosed
CN-114262330-B Fascaplysin derivative, preparation method and application thereof in resisting MRSA 宁波大学 2023-12-12 CN disclosed
CN-115160217-A Preparation method of Perampanel, synthetic intermediate and preparation method of degradation impurities 山东达因海洋生物制药股份有限公司 2022-10-11 CN disclosed
CN-112912047-A Microneedle array patch with glucose responsive matrix for closed-loop insulin delivery 北卡罗莱纳州立大学 2021-06-04 CN disclosed
CN-110028442-B Simple preparation method of Perampanel 新发药业有限公司 2020-07-17 CN disclosed
US-9115136-B2 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-08-25 US disclosed
US-8921379-B2 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-12-30 US disclosed
US-20140046056-A1 FUSED RING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-02-13 US disclosed
US-20100197683-A1 FUSED RING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-08-05 US disclosed
WO-2010087515-A1 FUSED RING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 WO disclosed
US-20100168070-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE HEINE NIKLAS 2010-07-01 US disclosed
US-20100144681-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATION GMNB (DE) 2010-06-10 US disclosed
EP-0675118-B1 Biphenylderivatives, process for their preparation and their use as medicaments EISAI CO LTD (JP) 2002-10-09 EP disclosed
US-6281214-B1 USEFUL FOR TREATING AND AMELIORATING MENTAL DISORDERS EISAI CO., LTD (JP) 2001-08-28 US disclosed
JP-H11152269-A BIPHENYLAMINDINE DERIVATIVE TEIJIN LTD 1999-06-08 JP disclosed
US-5849912-A Biphenyl derivatives EISAI CO., LTD. (JP) 1998-12-15 US disclosed
EP-0675118-A2 Biphenylderivatives, process for their preparation and their use as medicaments Eisai Co., Ltd. (JP) 1995-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140046056-A1 FUSED RING COMPOUND AND USE THEREOF PPARA, PPARG, AGTR2 GAA 1880/4885POLB 2330/4885TSHR 542/4885
US-20100168070-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN1, PSEN2, ADORA3 GAA 191/4885POLB 654/4885TSHR 2173/4885
US-20100144681-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN1, PSEN2, ADORA3 GAA 207/4885POLB 685/4885TSHR 2133/4885
US-20100197683-A1 FUSED RING COMPOUND AND USE THEREOF PPARA, PPARG, AGTR2 GAA 1880/4885POLB 2330/4885TSHR 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.